Cancer genomics: technology, discovery, and translation

Journal of Clinical Oncology

Volumn 30, Issue 6, 2012, Pages 647-660

  Tran, Ben ^a   Dancey, Janet E ^b   Kamel Reid, Suzanne ^c   McPherson, John D ^b,d   Bedard, Philippe L ^a   Brown, Andrew M K ^b   Zhang, Tong ^c   Shaw, Patricia ^c   Onetto, Nicole ^b,d   Stein, Lincoln ^b,d   Hudson, Thomas J ^b,d   Neel, Benjamin G ^d,e   Siu, Lillian L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOINFORMATICS; CANCER GENETICS; CANCER THERAPY; DNA METHYLATION; EPIGENETICS; EXOME; FEASIBILITY STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC TRANSCRIPTION AND TRANSLATION; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; MEDICAL ETHICS; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; WHOLE GENOME SEQUENCING;

CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GENETIC TECHNIQUES; GENOMICS; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMAN GENOME PROJECT; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS; ONTARIO; PROTEIN BIOSYNTHESIS;

EID: 84863393678     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.2316     Document Type: Review

References (129)

1. National Cancer Institute: Dictionary of cancerterms: Personalizedmedicine.http://www.cancer.gov/dictionary?CdrID=561717
2. National Cancer Institute: Office of Cancer Genomics. http://ocg.cancer.gov/
3. Sjöblom T, Jones S, Wood LD, et al: The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274, 2006 (Pubitemid 44571966)
4. Metzker ML: Sequencing technologies: The next generation. Nat Rev Genet 11:31-46, 2009
5. Shendure J, Ji H: Next-generation DNA sequencing. Nat Biotechnol 26:1135-1145, 2009
6. International Human Genome Consortium: Finishing the euchromatic sequence of the human genome. Nature 431:931-945, 1992
7. Robison K: Application of second-generation sequencing to cancer genomics. Brief Bioinform 11:524-534, 2010
8. Lin J, Li M: Molecular profiling in the age of cancer genomics. Exp Rev Mol Diagn 8:263-276, 2008 (Pubitemid 351724706)
9. Ajay SS, Parker SC, Abaan HO, et al: Accurate and comprehensive sequencing of personal genomes. Genome Res 21:1498-1505, 2011
10. Zhao J, Grant SF: Advances in whole genome sequencing technology. Curr Pharm Biotechnol 12:293-305, 2011
11. Eid J, Fehr A, Gray J, et al: Real-time DNA sequencing from single polymerase molecules. Science 323:133-138, 2009
12. Rohde H, Qin J, Cui Y, et al: Open-source genomic analysis of shiga-toxin-producing E. coli O104:H4. N Engl J Med 365:718-724, 2011
13. Twyman RM, Primrose SB: Techniques patents for SNP genotyping. Pharmacogenomics 4:67-79, 2003 (Pubitemid 36104657)
14. Isler JA, Vesterqvist OE, Burczynski ME: Analytical validation of genotyping assays in the biomarker laboratory. Pharmacogenomics 8:353-368, 2007 (Pubitemid 46585498)
15. Brion M, Quintela I, Sobrino B, et al: New technologies in the genetic approach to sudden cardiac death in the young. Forensic Sci Int 203:15-24, 2010
16. Tsuchihashi Z, Dracopoli N: Progress in high throughput SNP genotyping methods. Biosystems 2:103-110, 2002 (Pubitemid 34982213)
17. Pati N, Schowinsky V, Kokanovic O, et al: A comparison between SNaPshot, pyrosequencing, and biplex invader SNP genotyping methods: Accuracy, cost, and throughput. J Biochem Biophys Methods 60:1-12, 2004 (Pubitemid 38952847)
18. Koumi P, Green HE, Hartley S, et al: Evaluation and validation of the ABI 3700, ABI 3100, and the MegaBACE 1000 capillary array electrophoresis instruments for use with short tandem repeat microsatellite typing in a forensic environment. Electrophoresis 25:2227-2241, 2004 (Pubitemid 39136345)
19. Curtis C, Lynch AG, Dunning MJ, et al: The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics 10: 588, 2009
20. Voidonikolas G, Kreml SS, Chen C, et al: Basic principles and technologies for deciphering the genetic map of cancer. World J Surg 33:615-629, 2009
21. Teer JK, Mullikin JC: Exome sequencing: The sweet spot before whole genomes. Hum Mol Genet 19:145-151, 2010
22. Thomas RK, Baker AC, Debiasi RM, et al: High-throughput oncogene mutation profiling in human cancer. Nature Genet 39:347-351, 2007 (Pubitemid 46328493)
23. Dias-Santagata D, Akhavanfard S, David SS, et al: Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med 2:146-158, 2010
24. MacConaill LE, Campbell CD, Kehoe SM, et al: Profiling critical cancer gene mutations in clinical tumor samples. PloS One 4:e7887, 2009
25. Sauter G, Lee J, Bartlett JM, et al: Guidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerations. J Clin Oncol 27:1323-1333, 2009
26. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
27. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
28. Davies JJ, Wilson IM, Lam WL: Array CGH technologies and their applications to cancer genomes. Chromosome Res 13:237-248, 2005
29. Andrews J, Kennette W, Pilon J, et al: Multiplatform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number. PloS One 5:e8665, 2010
30. Pop M, Salzberg SL: Bioinformatics challenges of new sequencing technology. Trends Genet 24:142-149, 2008
31. Teufel A, Krupp M, Weinmann A, et al: Current bioinformatics tools in genomic biomedical research. Int J Mol Med 17:967-973, 2006
32. Saeys Y, Inza I, Larrañaga P: A review of feature selection techniques in bioinformatics. Bioinformatics 23:2507-2517, 2007 (Pubitemid 350048351)
33. Pandya GA, Holmes MH, Sunkara S, et al: A bioinformatic filter for improved base-call accuracy and polymorphism detection using the Affymetrix GeneChip whole-genome resequencing platform. Nucleic Acids Res 35:e148, 2007
34. Ding L, Ellis MJ, Li S, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999-1005, 2010
35. Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066, 2009
36. Pleasance ED, Stephens PJ, O'Meara S, et al: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463:184-190, 2010
37. Pleasance ED, Cheetham RK, Stephens PJ, et al: A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191-196, 2010
38. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
39. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
40. Berger MF, Lawrence MS, Demichelis F, et al: The genomic complexity of primary human prostate cancer. Nature 470:214-220, 2011
41. Ley TJ, Mardis ER, Ding L, et al: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456:66-72, 2008
42. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 458:719-724, 2009
43. International Cancer Genome Consortium: International network of cancer genome projects. Nature 464:993-998, 2010
44. Hirschhorn JN, Daly MJ: Genome-wide association studies for common diseases and complex traits. Nature Rev Genet 6:95-108, 2005 (Pubitemid 40179532)
45. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
46. Puente XS, Pinyol M, Quesada V, et al: Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101-105, 2011
47. Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806, 2008
48. Chapman MA, Lawrence MS, Keats JJ, et al: Initial genome sequencing and analysis of multiple myeloma. Nature 471:467-472, 2011
49. Totoki Y, Tatsuno K, Yamamoto S, et al: High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 43:464-469, 2011
50. Esteller M: Epigenetics in cancer. N Engl J Med 358:1148-1159, 2008
51. Kim K, Zakharkin SO, Allison DB: Expectations, validity, and reality in gene expression profiling. J Clin Epidemiol 63:950-959, 2010
52. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
53. Vijver MJ van de, He YD, Veer LJ van't, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002 (Pubitemid 35461656)
54. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
55. Wang E, Panelli MC, Marincola FM: Gene profiling of immune responses against tumors. Cur Opin Immunol 17:423-427, 2005 (Pubitemid 40848546)
56. Pardoll DM: Spinning molecular immunology into successful immunotherapy. Nature Rev Immunol 2:227-238, 2002
57. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964, 2006 (Pubitemid 44498003)
58. Bedognetti D, Wang E, Sertoli MR, et al: Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Exp Rev Vaccines 9:555-565, 2010
59. Coppola D, Nebozhyn M, Khalil F, et al: Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Path 179:37-45, 2011
60. Hanash S, Taguchi A: The grand challenge to decipher the cancer proteome. Nature Rev Cancer 10:652-660, 2010
61. Weinberg R: Point: Hypotheses first. Nature 464:678, 2010
62. Heng HH: Cancer genome sequencing: The challenges ahead. Bioessays 29:783-794, 2007
63. Ng SB, Turner EH, Robertson PD, et al: Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461:272-276, 2009
64. Maher B: Exome sequencing takes centre stage in cancer profiling. Nature 459:146-147, 2009
65. Cirulli ET, Singh A, Shianna KV, et al: Screening the human exome: A comparison of whole genome and whole transcriptome sequencing. Genome Biol 11:R57, 2010
66. Diamandis EP, Hudson T, Kallioniemi O, et al: Cancer genomes. Clin Chem 56:1660-1664, 2010
67. Strausberg RL, Simpson AJ: Whole-genome cancer analysis as an approach to deeper understanding of tumour biology. Br J Cancer 102:243-248, 2010
68. Ng PC, Levy S, Huang J, et al: Genetic variation in an individual human exome. PLoS Genet 4:e1000160, 2008
69. Walter MJ, Graubert TA, Dipersio JF, et al: Next-generation sequencing of cancer genomes: Back to the future. Per Med 6:653, 2009
70. Bell DW: Our changing view of the genomic landscape of cancer. J Path 220:231-243, 2010
71. Tran B, Kopetz S, Tie J, et al: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer [epub ahead of print on March 31, 2011]
72. Mardis ER, Wilson RK: Cancer genome sequencing: A review. Hum Mol Genet 18:R163-R168, 2009
73. Scott KL, Kabbarah O, Liang MC, et al: GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 459:1085-1090, 2009
74. Stein LD: Integrating biological databases. Nat Rev Genet 4:337-345, 2003
75. Kemmeren P, Holstege FC: Integrating functional genomics data. Biochem Soc Trans 31:1484-1487, 2003 (Pubitemid 38031007)
76. Manly KF, Nettleton D, Hwang JT: Genomics, prior probability, and statistical tests of multiple hypotheses. Genome Res 14:997-1001, 2004 (Pubitemid 38811535)
77. Nadon R, Shoemaker J: Statistical issues with microarrays: Processing and analysis. Trends Genet 18:265-271, 2002 (Pubitemid 34607142)
78. Martin LJ, Woo JG, Avery CL, et al: Multiple testing in the genomics era: Findings from Genetic Analysis Workshop 15, Group 15. Genet Epidemiol 31:124-131, 2007
79. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov 1:727-730, 2002 (Pubitemid 37361545)
80. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
81. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2011
82. Kim E, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
83. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
84. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
85. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
86. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
87. Gonzalez-Angulo AM, Hennessy BT, Mills GB: Future of personalized medicine in oncology: A systems biology approach. J Clin Oncol 28:2777-2783, 2010
88. Macconaill LE, Garraway LA: Clinical implications of the cancer genome. J Clin Oncol 28:5219-5228, 2010
89. Dancey JE, Dobbin KK, Groshen S, et al: Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 16:1745-1755, 2010
90. Doroshow JH: Selecting systemic cancer therapy one patient at a time: Is there a role for molecular profiling of individual patients with advanced solid tumors? J Clin Oncol 28:4869-4871, 2010
91. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al: Pilot study using molecular profiling of patients tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877-4883, 2010
92. Tsimberidou AM, Iskander NG, Hong DS, et al: Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center initiative. J Clin Oncol 29:18s, 2011 (suppl; abstr CRC2500)
93. Kim ES, Herbst RS, Wistuba II, et al: The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discov 1:44-53, 2011
94. Ross CJ, Katzov-Eckert H, Dubé MP, et al: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genet 41:1345-1349, 2009
95. de Haas EC, Zwart N, Meijer C, et al: Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol 26:1817-1823, 2008
96. O'Dwyer PJ, Catalano RB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: Practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24:4534-4538, 2006 (Pubitemid 46630947)
97. Tran B, Dancey JE, Kamel-Reid S, et al: Generation of a panel of druggable mutation cancer genes for molecular profiling in a feasibility study of somatic mutation genotyping and targeted exome sequencing: OICR-PMH study. Presented at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Annual Meeting on Molecular Markers in Cancer, Brussels, Belgium, October 27-29, 2011
98. Vakiani E, Janakiraman M, Shen R, et al: Comparative genomic analysis of primary versus metastasis in colorectal carcinomas. J Clin Oncol 29:15s, 2011 (suppl; abstr 10500)
99. Tie J, Gibbs P, Lipton L, et al: Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer 128:2075-2084, 2010
100. Amir E, Miller N, Geddie W, et al: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30:587-592, 2012
101. Janes CH, Lindor KD: Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 118:96-98, 1993
102. Sawyers CL: The cancer biomarker problem. Nature 452:548-552, 2008
103. Li J, Wang K, Jensen TD, et al: Tumor heterogeneity in neoplasms of breast, colon, and skin. BMC Res Notes 3:321, 2010
104. Kopetz S, Desai J, Chan E, et al: PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 3534)
105. Leiva IM, Emmert-Buck MR, Gillespie JW: Handling of clinical tissue specimens for molecular profiling studies. Curr Issues Mol Biol 5:27-35, 2003 (Pubitemid 36675581)
106. Klimecki WT, Futscher BW, Dalton WS: Effects of ethanol and paraformaldehyde on RNA yield and quality. BioTechniques 16:1021-1023, 1994
107. Ben-Ezra J, Johnson DA, Rossi J, et al: Effect of fixation on the amplification of nucleic acids from paraffin-embedded material by the polymerase chain reaction. J Histochem Cytochem 39:351-354, 1991
108. Coura R, Prolla JC, Meurer L, et al: An alternative protocol for DNA extraction from formalin fixed and paraffin wax embedded tissue. J Clin Path 58:894-895, 2005 (Pubitemid 41113404)
109. Bonner RF: Laser capture microdissection: Molecular analysis of tissue. Science 278:1481-1483, 1997
110. Hunt JL, Finkelstein SD: Microdissection techniques for molecular testing in surgical pathology. Arch Path Lab Med 128:1372-1378, 2004 (Pubitemid 39627474)
111. Cardoso J, Molenaar L, de Menezes RX, et al: Genomic profiling by DNA amplification of laser capture microdissected tissues and array CGH. Nucleic Acids Res 32:e146, 2004
112. Ioannidis JP: Is molecular profiling ready for use in clinical decision making? Oncologist 12:301-311, 2007
113. Brazma A, Hingamp P, Quackenbush J, et al: Minimum information about a microarray experiment (MIAME): Toward standards for microarray data. Nat Genet 29:365-371, 2001 (Pubitemid 34326681)
114. Ardekani AM, Petricoin EF, Hackett JL: Molecular diagnostics: An FDA perspective. Expert Rev Mol Diagn 3:129-140, 2003 (Pubitemid 36313747)
115. US Food and Drug Administration: Device advice: Investigational device exemption (IDE). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/default.htm
116. Harismendy O, Ng PC, Strausberg RL, et al: Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol 10:R32, 2009
117. Bhagwat NR, Roginskaya VY, Acquafondata MB, et al: Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 69:6831-6838, 2009
118. Olaussen KA, Fouret P, Kroemer G: ERCC1-specific immunostaining in non-small-cell lung cancer. N Engl J Med 357:1559-1561, 2007 (Pubitemid 47572656)
119. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
120. My Cancer Genome: Genetically informed cancer medicine. http://www.mycancergenome.org
121. McGuire AL, Caulfield T, Cho MK: Research ethics and the challenge of whole-genome sequencing. Nat Rev Genet 9:152-156, 2008 (Pubitemid 351147709)
122. Fabsitz RR, McGuire A, Sharp RR, et al: Ethical and practical guidelines for reporting genetic research results to study participants: Updated guidelines from a National Heart, Lung, and Blood Institute Working Group. Circ Cardiovasc Genet 3:574-580, 2010
123. Bookman EB, Langehorne AA, Eckfeldt JH, et al: Reporting genetic results in research studies: Summary and recommendations of an NHLBI working group. Am J Med Genet 140:1033-1040, 2006
124. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
125. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
126. Ortiz TM, Joshi VA, Heon S, et al: The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI). J Clin Oncol 29:15s, 2011 (suppl; abstr 7517)
127. Sequist LV, Heist RS, Shaw AT, et al: SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol 29:15s, 2011 (suppl; abstr 7518)
128. Bild AH, Potti A, Nevins JR: Linking oncogenic pathways with therapeutic opportunities. Nature Rev Cancer 6:735-741, 2006 (Pubitemid 44304232)
129. Harris TJ, McCormick F: The molecular pathology of cancer. Nat Rev Clin Oncol 7:251-265, 2010